Article Details

ENHANCING GASTRIC ULCER MANAGEMENT: NOVEL INSIGHTS FROM TERAZOSIN-PANTOPRAZOLE COMBINATION THERAPY

Teresa J. Vadakutta and Gaurav M. Doshia *

a Department of Pharmacology, SVKM’s Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai- 400 056, Maharashtra, India

* For Correspondence: E-mail: gaurav.pharmacology@gmail.com

 

https://doi.org/10.53879/id.61.01.14392


ABSTRACT

In this present study, we explored a novel approach to gastric ulcer management by investigating the therapeutic potential of terazosin, an alpha-1 adrenergic receptor inhibitor, in combination with pantoprazole, a common anti-ulcer agent. Employing an ethanol-induced rat-gastric ulcer model, the study demonstrated that terazosin pre-treatment significantly reduced ulcer formation, with the terazosinpantoprazole combination exhibiting superior mucosal protection compared to pantoprazole alone. Histopathological analysis revealed preserved mucosal structure and reduced neutrophil infiltration, indicating an anti-inflammatory effect. At a molecular level, the combination treatment groups exhibited elevated levels of phosphoglycerate kinase 1 (PGK-1), a vital enzyme in cellular energy metabolism, while inflammatory markers IκB kinase (IKK) and interleukin- 6 (IL-6) were significantly reduced, signifying mitigation of inflammation. These findings of the three different combinations of terazosin with pantoprazole indicate that this can be a potential approach for the treatment of gastric ulcers and can help in reducing the existing pantoprazole dose.

Year 2024 | Volume No. 61 | Issue No.1 | Page No. 77-85
Recent Issue
Current Issue
May 2024
Quick Contact